What Hair Loss Medications Actually Do
Finasteride and minoxidil are medications that may help slow hair loss progression. However, revitalizing already thinned and atrophied hair follicles falls outside the scope of what these drugs can accomplish. Distinguishing between what medications can and cannot do is essential for developing realistic treatment plans.
The core of androgenetic alopecia (male pattern and female pattern hair loss) is follicle miniaturization. When exposed to DHT (dihydrotestosterone), hair follicles gradually become smaller. Hair doesn't disappear all at once—rather, the growth phase shortens and the resting phase lengthens, causing thick hair to become fine like down. Androgenetic alopecia is the most common form of hair loss and represents a challenging area for treatment.(Gupta Aditya K et al., 2022)
Oral finasteride 1mg is an approved treatment for male androgenetic alopecia.(Gupta A K et al., 2022) This medication's role is to block the process by which DHT causes follicle miniaturization, thereby slowing progression. Slowing progression and filling in new growth are different issues. Some people discontinue the medication after 6 months because they haven't seen increased fullness, but the fact that progression has stopped may itself be a sign that the medication is working effectively. Conversely, attempting to restore areas where the crown is already extensively thinned using medication alone doesn't align with how these drugs actually work.
The DHT-Blocking Mechanism of Finasteride and Dutasteride
Finasteride and dutasteride belong to the same class of medications. Both drugs inhibit 5-alpha reductase (the enzyme that converts testosterone to DHT), thereby reducing DHT levels in the scalp. When DHT levels decrease, the stimulus causing follicle miniaturization weakens and progression may slow.
The difference lies in which form of the enzyme they block. Finasteride selectively inhibits 5-alpha reductase type 2, while dutasteride inhibits both types 1 and 2. Since both forms are distributed in scalp follicles, dutasteride is known to reduce blood DHT levels more significantly. However, greater DHT reduction doesn't necessarily translate to better outcomes for all patients, and pharmacokinetics, clinical efficacy, and safety must be evaluated separately for each medication.(Gupta A K et al., 2022)
Clinical data clarifies the effectiveness. In men with androgenetic alopecia taking finasteride 1mg daily, an average increase in hair density of 12.4 hairs/cm² at 24 weeks and 16.4 hairs/cm² at 48 weeks has been reported.(Gupta A K et al., 2022) The effects appear to accumulate over time, but these are average figures, and actual response varies among individuals depending on remaining follicle status and progression stage. Meaningful changes typically take 3-6 months to become apparent, and 6-12 months is reasonable for determining stability.
One important fact: when the medication is discontinued, DHT levels return to their original state. The drug doesn't change the follicles' DHT sensitivity itself—it only suppresses the enzyme. Hair loss tends to resume at pre-treatment levels within months to a year after discontinuation, so treatment should be started with long-term use in mind.
Minoxidil's Follicle Environment Enhancement Mechanism
Minoxidil works differently from finasteride. Rather than blocking DHT production, it intervenes in the follicular environment to change conditions for hair growth.
While it's often simply explained as "scalp blood flow expansion," the full efficacy is difficult to explain in one line clinically. The established primary mechanism is vasodilation through ATP-sensitive potassium channel opening, while Wnt/β-catenin pathway stimulation and other mechanisms suggested in preclinical studies are still being researched for clinical significance. It's understood to work by shifting resting follicles toward the growth phase.
There are two forms available. Topical minoxidil, applied directly to the scalp, has been used for a long time, but maintaining twice-daily application consistently can be challenging in practical use. Low-dose oral minoxidil may be considered as an alternative for some patients who have difficulty using topical formulations, and evidence regarding its efficacy and tolerability is accumulating. Individual responses may vary.(Randolph Michael et al., 2021) However, since oral formulations have systemic effects, they require monitoring for edema, hypertrichosis, cardiovascular symptoms, and assessment of baseline conditions like blood pressure, cardiac function, and liver function before prescribing.
The timing of response onset and gradual return to baseline upon discontinuation is similar to finasteride. While they work at different points, the structure of "response is maintained while treatment continues" is the same.
Areas Beyond Medication Reach
Finasteride reduces DHT production, and minoxidil improves the follicular environment. Both medications are tools that intervene in progression speed. However, when follicles have already undergone prolonged miniaturization and are structurally atrophied, or when surrounding tissue has progressed to fibrosis, it can be difficult to reverse these structures through medication alone.(Gupta A K et al., 2022)
When treatment is started in the early stages as crown parting begins to widen, there are reports of response to progression inhibition, though individual responses may vary. In contrast, when medication is started at a stage where the crown is already extensively thinned, while the rate of loss may decrease, there are limitations to how much the thinned areas can be restored through medication alone. Androgenetic alopecia is similar to a chronic progressive condition based on genetic susceptibility, so treatment periods are not short.
Therefore, how to address areas outside the scope of medication becomes a separate topic in clinical practice. Approaches that stimulate the follicular environment itself include options like PRP (platelet-rich plasma scalp injections), perifollicular mesotherapy (microinjections), and exosome (signaling particles secreted by cells) based regenerative injection treatments that are being considered. These don't block DHT production or dilate blood vessels, but rather stimulate the signaling environment around follicles to enhance growth conditions. Medications still play the role of slowing progression, while regenerative stimulation complements areas that medication cannot reach.
Safety Monitoring Items
The most commonly reported adverse reactions with finasteride are sexual function-related changes. Decreased libido, erectile changes, and reduced ejaculatory volume may occur in some users, with reported frequencies varying depending on study design.(Gupta A K et al., 2022) Most are known to recover when the medication is discontinued, but some cases report persistent or newly emerging sexual function or mood-related symptoms even after discontinuation, referred to as post-finasteride syndrome (PFS). The incidence and mechanisms of PFS are still being researched,(Gupta A K et al., 2022) and while it's not a common occurrence, the practice of thoroughly explaining the possibility to patients before starting medication has become established.
Depression or mood changes are also reported in some patients. While causality hasn't been established in all cases, if emotional changes are experienced after starting the medication, it's safe to inform healthcare providers.(Gupta A K et al., 2022)
With minoxidil, scalp irritation or itching during topical application is relatively common, and oral minoxidil requires monitoring for systemic adverse reactions such as edema, hypertrichosis, and cardiovascular burden. Both medications require baseline assessment before prescribing and regular follow-up monitoring.
The Core of Hair Loss Medications
Finasteride and minoxidil are medications with evidence for slowing the progression of androgenetic alopecia, and there are reports that early initiation may preserve more follicles, though responses may vary depending on individual conditions.(Gupta Aditya K et al., 2022) Both medications operate on the premise of long-term use, and when discontinued, a gradual return to pre-treatment status is observed. It's realistic to decide whether to start treatment with the understanding that it's "treatment where response is maintained while taking the medication."
The role of medication is to preserve the current state. Approaches to already long-atrophied follicles and extensively thinned areas should be considered alongside why medication alone isn't enough and the crucial differences in regenerative treatments. When it becomes clear whether the highest priority goal at the current stage is slowing progression or recovering thinned areas, the role of medication also becomes clear.
This content is provided for medical information purposes and may vary depending on individual conditions. Please consult with specialists for accurate diagnosis and treatment.
Related medical definitions can be found at Linkare Knowledge: Androgenetic Alopecia.
References
- Gupta A K, Venkataraman M, Talukder M (2022). Finasteride for hair loss: a review.. J Dermatolog Treat. PMID: 34291720
- Gupta Aditya K, Talukder Mesbah, Williams Greg (2022). Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.. J Dermatolog Treat. PMID: 35920739
- Randolph Michael, Tosti Antonella (2021). Oral minoxidil treatment for hair loss: A review of efficacy and safety.. J Am Acad Dermatol. PMID: 32622136
Frequently Asked Questions
Q. What should I do if side effects occur while taking finasteride?
Sexual function-related adverse reactions such as decreased libido and erectile changes, as well as mood changes like depression, are reported in some users. Most recover when the medication is discontinued, but post-finasteride syndrome (PFS) cases where symptoms persist or newly appear even after discontinuation are rarely reported. If symptoms persist or affect daily life, rather than discontinuing arbitrarily, it's appropriate to consult with the prescribing physician to determine whether dose adjustment or alternative medication review is needed.
Q. Is it normal that hair loss seems to increase when starting medication?
In the initial 1-2 months, the amount of hair loss may actually increase in some cases. This is a temporary phenomenon as resting hair is replaced by new growth phase hair, and discontinuing medication during this period would be most disadvantageous. If the pattern of change differs from usual or if excessive hair loss occurs, it's safe to consult with healthcare providers.
Q. Can women use finasteride or minoxidil?
Oral finasteride is restricted for women of childbearing age due to risk of fetal malformations. However, topical minoxidil has evidence for use in female androgenetic alopecia, and low-dose oral minoxidil may also be considered for some patients. However, indications and dosages vary depending on gender, age, and health status, so individual consultation with a physician is necessary.
Q. Are there cases where hair loss medications are used together with hair transplants and regenerative treatments?
Hair transplants and regenerative treatments (PRP, mesotherapy, exosomes, etc.) are approaches that complement areas medication cannot reach, while drug therapy plays the role of slowing progression in remaining follicles. Since they work at different points, combining medication therapy to preserve existing follicles even after procedures is commonly considered in clinical practice.
Q. At what age is it appropriate to start hair loss medication?
Androgenetic alopecia can begin progressing even in the early twenties, and the effectiveness of drug therapy tends to have a wider maintainable range when started while follicles are still functioning. However, the timing of initiation should comprehensively consider factors such as hair loss progression speed, overall health status, and ability to take medication, making it difficult to establish uniform criteria based on age alone.